Magdeburg researchers discover a new mechanism of cancer immune defense
Modern immunotherapies boost the body's own defenses against cancer. They activate killer T cells of the immune system that can specifically recognize and destroy cancer cells. In many patients, however, cancer cells adapt and become invisible to killer T cells so that the treatment is no longer effective. An interdisciplinary team of researchers from Magdeburg has now discovered a new mechanism that enables the immune system to also eliminate such invisible cancer cells. (Source: World Pharma News)
Source: World Pharma News - June 23, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
FDA approves first gene therapy for treatment of certain patients with Duchenne muscular dystrophy
Today, the U.S. Food and Drug Administration approved Elevidys, the first gene therapy for the treatment of pediatric patients 4 through 5 years of age with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who do not have a pre-existing medical reason preventing treatment with this therapy. (Source: World Pharma News)
Source: World Pharma News - June 22, 2023 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Pfizer & #039;s TALZENNA ® in combination with XTANDI® receives U.S. FDA approval
Pfizer (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI (enzalutamide), for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Source: World Pharma News)
Source: World Pharma News - June 21, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
The first year of the Long COVID project: What has been achieved?
Since the 1st of June 2022, the Long COVID Consortium, led by HUS Helsinki University Hospital, is working to elucidate the predisposing factors and mechanisms for the development of Long COVID Syndrome (LCS). This is essential to be able to develop and improve the care of patients suffering from the long-term effects of COVID-19 infection. (Source: World Pharma News)
Source: World Pharma News - June 21, 2023 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news
New anti-coagulants may help treat sepsis and COVID-19
Scientists from Trinity College Dublin have just discovered that the drug dimethylfumarate can block blood clotting during infection, offering hope that it could be used to treat a number of conditions, such a life-threatening disseminated intravascular coagulopathy (DIC), which can occur in serious infections with bacteria that lead to sepsis or in response to viral infections such as COVID-19. (Source: World Pharma News)
Source: World Pharma News - June 20, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
For resistant breast cancers, two drugs may be better than one
Cancer cells are even smarter than scientists previously believed, according to new CU Boulder research. When these cells are confronted with potent new drugs called CDK2 inhibitors, which are designed to prevent cancer from proliferating, they can trigger a workaround to survive the assault in as little as one to two hours. (Source: World Pharma News)
Source: World Pharma News - June 19, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Real-world evidence highlights the urgent need to act on the growing global burden of chronic kidney disease
AstraZeneca, a leader in cardiorenal diseases, presented new real-world evidence (RWE) data at the European Renal Association (ERA) 2023 Congress in Milan, Italy, demonstrating the staggeringly low rate of diagnosis in chronic kidney disease (CKD). These data show that an urgent need exists for improved screening which can lead to earlier diagnosis.
Results from the REVEAL-CKD multinational study showed that the prevalence of undiagnosed Stage 3 (moderate) CKD was 85% to 97% across Spain, Australia, Canada and Brazil. (Source: World Pharma News)
Source: World Pharma News - June 16, 2023 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Tethering of shattered chromosomal fragments paves way for new cancer therapies
Healthy cells work hard to maintain the integrity of our DNA, but occasionally, a chromosome can get separated from the others and break apart during cell division. The tiny fragments of DNA then get reassembled in random order in the new cell, sometimes producing cancerous gene mutations.
This chromosomal shattering and rearranging is called “chromothripsis” and occurs in the majority of human cancers, especially cancers of the bones, brain and fatty tissue. (Source: World Pharma News)
Source: World Pharma News - June 15, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Scientists discover small RNA that regulates bacterial infection
People with weakened immune systems are at constant risk of infection. Pseudomonas aeruginosa, a common environmental bacterium, can colonize different body parts, such as the lungs, leading to persistent, chronic infections that can last a lifetime - a common occurrence in people with cystic fibrosis.
But the bacteria can sometimes change their behavior and enter the bloodstream, causing chronic localized infections to become acute and potentially fatal. (Source: World Pharma News)
Source: World Pharma News - June 14, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology
Bayer and Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, announced an exclusive license agreement to develop and commercialize Cedilla Therapeutics' CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers.
Overexpression or genetic activation of Cyclin Dependent Kinase 2 (CDK2) binding partner cyclin E is a key oncogenic process in several cancers. (Source: World Pharma News)
Source: World Pharma News - June 13, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
AstraZeneca announces agreement with Quell Therapeutics to develop, manufacture and commercialise engineered T-regulatory cell therapies for autoimmune diseases
AstraZeneca has entered into an exciting collaboration, exclusive option and license agreement with Quell Therapeutics to develop multiple engineered T-regulator (Treg) cell therapies that have the potential to be curative in Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD) indications.
Under the terms of the agreement, Quell's proprietary toolbox of Treg cell engineering modules, including its innovative Foxp3 Phenotype Lock will be leveraged to develop autologous multi-modular Treg cell therapy candidates for major autoimmune disease indications. (Source: World Pharma News)
Source: World Pharma News - June 12, 2023 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Study shows metformin lowers the risk of getting long COVID
In a new study published in The Lancet Infectious Diseases, University of Minnesota researchers found that metformin, a drug commonly used to treat diabetes, prevents the development of long COVID.
The study, called COVID-OUT, investigated if early outpatient COVID-19 treatment with metformin, ivermectin or fluvoxamine could prevent long COVID. Long COVID is a chronic illness that can affect up to 10% of people who have had COVID-19. (Source: World Pharma News)
Source: World Pharma News - June 9, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Taurine may be a key to longer and healthier life
A deficiency of taurine - a nutrient produced in the body and found in many foods - is a driver of aging in animals, according to a new study led by Columbia researchers and involving dozens of aging researchers around the world.
The same study also found that taurine supplements can slow down the aging process in worms, mice, and monkeys and can even extend the healthy lifespans of middle-aged mice by up to 12%. (Source: World Pharma News)
Source: World Pharma News - June 8, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics
Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Acuitas' LNP technology will support Bayer's in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver. (Source: World Pharma News)
Source: World Pharma News - June 7, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
FDA announces additional steps to modernize clinical trials
Today, the U.S. Food and Drug Administration is announcing the availability of a draft guidance with updated recommendations for good clinical practices (GCPs) aimed at modernizing the design and conduct of clinical trials, making them more agile without compromising data integrity or participant protections. The updates are intended to help pave the way for more efficient clinical trials to facilitate the development of medical products. (Source: World Pharma News)
Source: World Pharma News - June 6, 2023 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
